DNAPrint Genomics Aandeel

DNAPrint Genomics Quick Ratio

De Snelle Ratio (Zuurtestratio) van DNAPrint Genomics (DNAG) per 20 aug 2026 bedraagt 0,50. In het voorgaande jaar bedroeg Snelle Ratio (Zuurtestratio) 0,20 — een verandering van 154,75% (hoger).

Quick Ratio

0,50

YoY

154,75%

Laatst bijgewerkt:

Snelle Ratio (Zuurtestratio) van DNAPrint Genomics is 2026 0,50 . Snelle Ratio (Zuurtestratio) van DNAPrint Genomics was 2025 0,20 . Het is daarmee 154,75% hoger lager dan het jaar ervoor.
Access this data via the Eulerpool API

DNAPrint Genomics Aandelenanalyse

Wat doet DNAPrint Genomics? DNAPrint Genomics Inc. was an American company specializing in researching genetic differences and their impact on health, diagnostics, and forensic applications. Founded in Sarasota, Florida in 1997, originally named Genaissance Pharmaceuticals, the company focused on medical research. In 2005, it changed its name to DNAPrint Genomics and shifted its focus to genetic testing development. The company's business model included developing and marketing molecular tests that can reveal an individual's genetic background, providing access to new markets and customers. DNAPrint Genomics offered various product lines for disease diagnosis, including tests for identifying and diagnosing specific diseases like breast cancer, colon cancer, and Alzheimer's. They also provided diagnostics for personalized medicine, matching medication to individuals' genetic predispositions. However, the company gained attention primarily for its forensic applications. They developed a system called DNAWitness, allowing comparison of unknown DNA samples with DNA databases to create offender profiles. The system was used by law enforcement agencies in the U.S. to aid crime investigation and was also involved in international police collaborations. DNAPrint Genomics pursued patents and partnerships with other companies to expand access to new technologies and developments, aiming to position itself in the international market. In 2008, the company announced its discontinuation due to economic reasons, facing complications in selling its DNAWitness system and encountering difficulties in selling its diagnostic tests. Despite having promising products, the company was unable to stabilize its market position and become profitable. DNAPrint Genomics is een van de meest populaire bedrijven op Eulerpool.

Veelgestelde vragen over het aandeel DNAPrint Genomics

Snelle Ratio (Zuurtestratio) van DNAPrint Genomics bedraagt 0,50 in 2026.

Snelle Ratio (Zuurtestratio) van DNAPrint Genomics is veranderd van 0,20 naar 0,50, wat een verandering van 154,75% vertegenwoordigt. De waarde is hoger dan het vorige jaar.

Op Eulerpool vindt u de volledige historische ontwikkeling van Snelle Ratio (Zuurtestratio) DNAPrint Genomics sinds 2006 – met jaarlijkse waarden, grafieken en gedetailleerde analyse.

De quick ratio meet de kortetermijnliquiditeit van een bedrijf zonder rekening te houden met voorraad.

Een 'goede' varieert per branche en bedrijfsfase. Op Eulerpool kunt u maatstaven direct vergelijken.

Access this data via the Eulerpool API

Hefboom — DNAPrint Genomics

Alle kengetallen — DNAPrint Genomics